Novo Nordisk Sues Sanofi-Aventis Over Insulin Delivery Patents

Law360, New York (September 6, 2005, 12:00 AM EDT) -- Danish drug maker Novo Nordisk A/S has sued its French rival Sanofi-Aventis over patents for its device for administering insulin to people living with diabetes.

Sanofi-Aventis’ handheld OptiClik is an insulin delivery device, or “insulin pen” for Type 1 and Type 2 diabetes. Novo Nordisk alleges the device infringes on of its patents, prompting the complaint filed in U.S. District Court for Delaware.

The complaint accuses Sanofi-Aventis of willful and deliberate infringement, while seeking attorney’s fees, as well as preliminary and permanent injunctions. Also named in...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.